Outpatient treatment for cancer condition offers effective new approach for patients

April 5, 2018, University of Bristol

A novel approach to treating fluid build-up around the lungs of cancer patients could deliver a more effective home-based treatment for thousands of people who might be approaching the end of their lives, according to a new study led by the University of Bristol and North Bristol NHS Trust.

In with all types of excess fluid can start to collect between the thin layers of tissue lining the outside of the and the wall of the chest cavity. This phenomenon, called a "malignant pleural effusion" and which is particularly prevalent in lung and , is estimated to affect at least 50,000 people in the UK each year with numbers increasing as both cancer survival and number of cancer diagnoses increases year-on-year.

As the lung becomes compressed by the surrounding fluid, patients will usually experience breathlessness and a dramatic reduction in quality of life. The commonest treatment for malignant effusions involves inserting a temporary tube between the ribs to drain the fluid, which allows the lung to expand. Before it is removed, medical talcum powder can be inserted down the tube to try to "glue" the lung to the inside of the chest wall to prevent further build-up of fluid.

However, while this treatment is relatively effective, the fact that it must be delivered in hospital over a number of days means that patients can experience additional distress because they unable to be at home or with family.

The alternative "indwelling pleural catheter", or IPC method, has become increasingly popular in the last two decades and is now offered by many hospitals in the UK. This approach involves patients only being in hospital for a few hours to have a long-term drainage tube tunnelled under a short section of skin in the chest. After this, their fluid can be drained at home as often as needed, rather than in the hospital environment. The main downside to this method, however, is that the tube may need to stay in place for many months or longer because, unlike talc, the method is not designed to prevent fluid formation.

In a recent study, published today [Wednesday 4 April] in the New England Journal of Medicine, researchers from the University of Bristol and North Bristol NHS Trust spent four years working with patients in 18 UK hospitals to assess whether an alternative treatment approach, which combined talc with an IPC, could be delivered to patients who preferred to remain at home rather than be admitted to hospital for their .

One hundred and fifty four patients were randomly treated as outpatients with either an IPC alone, or with an IPC in combination with talc. The study showed that those patients given talc through their IPC were more than twice as likely to have their fluid dry up than those who were just treated as standard, with an IPC alone.

Dr Rahul Bhatnagar, Clinical Lecturer in Respiratory Medicine, who co-ordinated the trial, and Nick Maskell, Professor of Respiratory Medicine, who led the study, from the Bristol Medical School (THS) at the University of Bristol, said: "This could change how malignant effusions are treated around the world.

"Our study shows that by combining two common but previously separate treatments, those with cancer-related around the lung can be more effectively managed at home than previously thought.

"For those who would prefer not to spend any time in , this combination is at least twice as good as any previous option. Most patients who are having an IPC should now be considered for talc treatment as well."

The researchers plan to continue to find ways to minimise the impact of malignant effusions on , particularly focusing on what patients feel is most important to them. The cost implications to the NHS of such a new are also being investigated.

Explore further: Study examines treatments for relieving breathing difficulties among patients with lung effusions

More information: 'Outpatient Talc Administration by Indwelling Pleural Catheter for Malignant Effusion' by Rahul Bhatnagar et al in New England Journal of Medicine [NEJM].

Related Stories

Study examines treatments for relieving breathing difficulties among patients with lung effusions

May 20, 2012
Helen E. Davies, M.D., of the University Hospital of Wales, Cardiff, and colleagues compared the effectiveness of treatments to relieve breathing difficulties among patients with malignant pleural effusion (presence of fluid ...

Water in the chest – new findings on pleural effusion

February 28, 2018
Lung cancer patients are particularly susceptible to malignant pleural effusion, when fluid collects in the space between the lungs and the chest wall. Researchers at the Helmholtz Zentrum München, in partnership with the ...

How cancer cells flood the lung

May 19, 2017
Lung cancer patients are particularly susceptible to malignant pleural effusion, when fluid collects in the space between the lungs and the chest wall. Researchers at the Helmholtz Zentrum München, in partnership with the ...

Effectiveness of pain medications for patients receiving treatment for lung condition

December 22, 2015
Use of NSAIDs vs opiates resulted in no significant difference in measures of pain but was associated with more rescue medication (additional medicine needed due to uncontrolled pain) among patients with malignant pleural ...

Unique lipid profile could help diagnose and treat lung cancer

September 8, 2017
The lipid contents of a fluid that surrounds the lungs in some diseases contains specific fats that could be used as a biomarker to distinguish people with and without lung cancer. It can also identify a subtype of the cancer ...

Recommended for you

Scientists break new ground in potential treatment of common form of leukaemia

December 19, 2018
Scientists at the University of Glasgow have discovered a potential combination therapy for the treatment of chronic lymphocytic leukaemia (CLL), the most common form of leukaemia in the Western world, diagnosed in more than ...

From eye drops to potential leukaemia treatment

December 19, 2018
An active ingredient in eye drops that were being developed for the treatment of a form of eye disease has shown promise for treating an aggressive form of blood cancer. Scientists at the Wellcome Sanger Institute, University ...

DNA 'webs' aid ovarian cancer metastasis, study reveals

December 19, 2018
Researchers from the University of Texas MD Anderson Cancer Center have discovered that ovarian cancer cells spread, or metastasize, to new tissue after being caught in DNA "webs" extruded by immune cells. The study, which ...

Two ways cancer resists treatment are actually connected, with one activating the other

December 18, 2018
Drugs that target BRAF and MEK in cancer have shown promise in treating a subset of melanoma that carries a mutation in the BRAF gene, but drug resistance usually emerges, reversing the benefit of these drugs and limiting ...

HPV discovery raises hope for new cervical cancer treatments

December 18, 2018
Researchers at the University of Virginia School of Medicine have made a discovery about human papillomavirus (HPV) that could lead to new treatments for cervical cancer and other cancers caused by the virus.

Vaccine, checkpoint drugs combination shows promise for pancreatic cancers

December 18, 2018
Researchers at the Johns Hopkins Kimmel Cancer Center discovered a combination of a cancer vaccine with two checkpoint drugs reduced pancreatic cancer tumors in mice, demonstrating a possible pathway for treatment of people ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.